These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 6121499

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Normalization of hyperreactive thrombocytes in patients with TIA by piracetam?].
    Grotemeyer KH, Hofferberth B, Hirschberg M.
    Nervenarzt; 1986 Mar; 57(3):180-3. PubMed ID: 3960236
    [No Abstract] [Full Text] [Related]

  • 3. [Use of piracetam (nootropil) in the rehabilitative treatment of the middle-aged and elderly who have had a stroke].
    Man'kovskiĭ NB, Kostiuchenko VG, Tereshchenko LA, Tordiia GD.
    Vrach Delo; 1980 Sep; (9):73-7. PubMed ID: 7423958
    [No Abstract] [Full Text] [Related]

  • 4. [Effect of piracetam on cerebral hemodynamics in patients with arteriosclerosis and dyscirculatory encephalopathy].
    Vesel'skiĭ ISh, Voroniuk MI.
    Klin Med (Mosk); 1986 Jun; 64(6):41-4. PubMed ID: 3747435
    [No Abstract] [Full Text] [Related]

  • 5. [Management of neuroleptic side-effects with piracetam (author's transl)].
    Sikora J, Kabes J, Pisvejc J.
    Cesk Psychiatr; 1981 Apr; 77(2):137-42. PubMed ID: 6114800
    [No Abstract] [Full Text] [Related]

  • 6. [Clinical experience with treatment by piracetam in gerontopsychiatry (author's transl)].
    Vencovský E, Hronek J, Drahokoupil L, Fait V, Hudcová T, Laciga Z, Vanková H.
    Cesk Psychiatr; 1980 Apr; 76(2):89-97. PubMed ID: 6994907
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Pilot study of 2-pyrrolidon-acetamid (generic name: piracetam) (author's transl)].
    Tacke B, Freistein H, Kempf H, Windheuser A.
    Pharmakopsychiatr Neuropsychopharmakol; 1975 Mar; 8(2):82-9. PubMed ID: 788004
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Nootropic drugs: effects and effectiveness. A reflection exemplified by a phase III study using piracetam].
    Herrmann WM, Kern U.
    Nervenarzt; 1987 Jun; 58(6):358-64. PubMed ID: 3302738
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Piracetam improves visuomotor and cognitive deficits in early Parkinsonism--a pilot study.
    Oepen G, Eisele K, Thoden U, Birg W.
    Pharmacopsychiatry; 1985 Nov; 18(6):343-6. PubMed ID: 4089014
    [Abstract] [Full Text] [Related]

  • 18. Inhibitory effect of piracetam on platelet-rich thrombus formation in an animal model.
    Stockmans F, Deberdt W, Nyström A, Nyström E, Stassen JM, Vermylen J, Deckmyn H.
    Thromb Haemost; 1998 Jan; 79(1):222-7. PubMed ID: 9459351
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients.
    Miyata M, Shirakawa T, Acharya B, Terao S, Gotoh A.
    ASAIO J; 2006 Jan; 52(3):272-5. PubMed ID: 16760715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.